Pharmaceutical

Intellia propels into 2024 with CRISPR pipeline updates

Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.

Jan 5, 2024 - 18:00
Intellia propels into 2024 with CRISPR pipeline updates
Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.
Read the original article

Tags:

Previous Article

Signal: UK online pharmacies selling prescription drugs without proper checks

Next Article

Insilico teams up with Menarini for breast cancer KAT6 inhibitor

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sionna raises $182m to double down in cystic fibrosis drug development

Sionna raises $182m to double down in cystic fibrosis d...

Mar 7, 2024

Dizal seeks FDA approval for NSCLC treatment sunvozertinib

Dizal seeks FDA approval for NSCLC treatment sunvozertinib

Nov 11, 2024

Opinion: How do doctors’ personal political affiliations affect how they care for their patients?

Opinion: How do doctors’ personal political affiliation...

Jul 24, 2023